Entera Bio Ltd

5DT

Company Profile

  • Business description

    Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

  • Contact

    Minrav Building - Fifth Floor
    Kiryat Hadassah
    Jerusalem9112002
    ISR

    T: +972 25327151

    E: [email protected]

    https://www.enterabio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    22

Stocks News & Analysis

stocks

We raise our near-term gold price assumptions

Our coverage remains overvalued.
stocks

Apple: Gemini partnership lets AI-worried investors breathe a sigh of relief

We believe a competitive—if not leading—AI feature suite will reinforce Apple’s wide-moat mobile device ecosystem.
stocks

ASX share ticks all the popular thematic boxes

The shares are overvalued as investors are overly excited about defence and gold exposure.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,151.800.100.00%
CAC 408,395.7648.560.58%
DAX 4025,415.724.94-0.02%
Dow JONES (US)49,191.99398.21-0.80%
FTSE 10010,167.8230.470.30%
HKSE26,999.81151.340.56%
NASDAQ23,709.8724.03-0.10%
Nikkei 22554,341.23792.071.48%
NZX 50 Index13,757.71101.660.74%
S&P 5006,963.7413.53-0.19%
S&P/ASX 2008,820.601.20-0.01%
SSE Composite Index4,126.0912.67-0.31%

Market Movers